ArticleInfection and drug resistance2017

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients.

Zhi-Wei Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.